Page last updated: 2024-12-06

nifuratel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nifuratel: Local antiprotozoal and antifungal agent that may also be given orally. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21054
MeSH IDM0014851

Synonyms (10)

Synonym
nifuratel
4936-47-4
FT-0603665
SRQKTCXJCCHINN-UHFFFAOYSA-N
mfcd00057257
5-(methylsulfanylmethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
D87752
DTXSID60863471
N1167
SY068782

Research Excerpts

Effects

ExcerptReferenceRelevance
"Nifuratel has a very safe toxicological profile."( Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review.
Mailland, F; Mendling, W, 2002
)
1.28
"Nifuratel has a very safe toxicological profile."( Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review.
Mailland, F; Mendling, W, 2002
)
1.28

Pharmacokinetics

ExcerptReferenceRelevance
" The results showed that the area under the plasma concentration-time curve (AUC), time to maximum observed plasma concentration (Tmax), maximum concentration reached in the concentration profile (Cmax), and elimination half-life (t1/2) between the test tablets and the reference tablets demonstrated no significant difference (P>0."( An improved HPLC method for determination of nifuratel in human plasma and its application to pharmacokinetics studies.
Guo, RC; Li, BY; Li, XL; Ni, MY; Wang, BJ,
)
0.39

Bioavailability

ExcerptReferenceRelevance
" Relative bioavailability is 104."( Determination of nifuratel in human plasma by HPLC and study on its pharmacokinetics.
Fu, J; Jiang, J; Wu, Y; Xiang, B; Yang, J, 2005
)
0.67
" The relative bioavailability amounted to 103."( An improved HPLC method for determination of nifuratel in human plasma and its application to pharmacokinetics studies.
Guo, RC; Li, BY; Li, XL; Ni, MY; Wang, BJ,
)
0.39

Dosage Studied

ExcerptRelevanceReference
"Nifuratel 500 mg showed good clinical efficacy for the treatment of AV, particularly mixed AV, and is superior to the 250 mg dosage in the treatment of mixed AV."( High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study.
Duan, Y; Li, N; Liang, Q; Song, S; Zhang, A, 2016
)
2.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (30.95)18.7374
1990's6 (14.29)18.2507
2000's12 (28.57)29.6817
2010's8 (19.05)24.3611
2020's3 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.34 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index87.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (19.61%)5.53%
Reviews4 (7.84%)6.00%
Case Studies8 (15.69%)4.05%
Observational0 (0.00%)0.25%
Other29 (56.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]